The FDA expanded Keytruda plus Padcev to all muscle-invasive bladder cancer patients on July 10, 2026. Here is who now qualifies and what the KEYNOTE-B15 trial showed.
FDA Expands Keytruda Approval to All Bladder Cancer Patients Before Surgery, Not Just Those Avoiding Chemo
by | Jul 24, 2026 | Uncategorized | 0 comments
Recent Comments